L-type amino acid transporter 1 expression is a prognostic marker in patients with surgically resected stage i non-small cell lung cancer

Histopathology

Volumn 54, Issue 7, 2009, Pages 804-813

  Imai, Hisao ^d   Kaira, Kyoichi ^d,e   Oriuchi, Noboru ^a   Yanagitani, Noriko ^d   Sunaga, Noriaki ^d   Ishizuka, Tamotsu ^d   Kanai, Yoshikatsu ^b   Endou, Hitoshi ^c   Nakajima, Takashi ^a   Mori, Masatomo ^d  

^a GUNMA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c KYORIN UNIVERSITY   (Japan)

^d Department of Medicine and Molecular Science ^*  (Japan)

^e GUNMA UNIVERSITY   (Japan)

Author keywords

Ki67; LAT1; Non small cell lung cancer; Prognostic factor; Stage I

Indexed keywords

AMINO ACID TRANSPORTER; KI 67 ANTIGEN; L TYPE AMINO ACID TRANSPORTER 1; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ADULT; AGED; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; REVIEW; SEX DIFFERENCE; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; LARGE NEUTRAL AMINO ACID-TRANSPORTER 1; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 66949138193     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2009.03300.x     Document Type: Review

References (26)

1. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small-cell lung cancer. A meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995 311 899 909.
2. Hoffman PC, Mauer AM, Vokes EE. Lung cancer. Lancet 2000 355 479 485. (Pubitemid 30085163)
3. Christensen HN. Role of amino acid transport and countertransport in nutrition and metabolism. Physiol. Rev. 1990 70 43 77. (Pubitemid 20037281)
4. McGivan JD, Pastor-Anglada M. Regulatory and molecular aspects of mammalian amino acid transport. Biochem. J. 1994 299 321 334. (Pubitemid 24114121)
5. Oxender DL, Christensen HN. Evidence for two types of mediation of neutral amino acid transport in Ehrlich cells. Nature 1963 197 765 767.
6. Kanai Y, Segawa H, Miyamoto K, Uchino H, Takeda E, Endou H. Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J. Biol. Chem. 1998 273 23629 23632. (Pubitemid 28435687)
7. Yanagida O, Kanai Y, Chairoungdua A et al. Human L-type amino acid transporter 1 (LAT 1): characterization of function and expression in tumor cell lines. Biochim. Biophys. Acta 2001 1514 291 302. (Pubitemid 32831016)
8. Ohkame H, Masuda H, Ishii Y, Kanai Y. Expression of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (4F2hc) in liver tumor lesions of rat models. J. Surg. Oncol. 2001 78 265 271. (Pubitemid 33097058)
9. Nakanishi K, Matsuo H, Kanai Y et al. LAT1 expression in normal lung and in atypical adenomatous hyperplasia and adenocarcinoma of the lung. Virchows Arch. 2006 448 142 150. (Pubitemid 43237879)
10. Nawashiro H, Otani N, Shinomiya N et al. L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors. Int. J. Cancer 2006 119 484 492. (Pubitemid 43955699)
11. Kaschten B, Stevenaert A, Sadzot B et al. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J. Nucl. Med. 1998 39 778 785. (Pubitemid 28216722)
12. Mountain CF. Revision in the International System for staging lung cancer. Chest 1997 11 1710 1717. (Pubitemid 27260107)
13. Chairoungdua A, Segawa H, Kim JY et al. Identification of an amino acid transporter associated with the cystinuria-related type II membrane glycoprotein. J. Biol. Chem. 1999 274 28845 28848.
14. Matsuo H, Tsukada S, Nakata T et al. Expression of a system L neutral amino acid transporter at the blood-brain barrier. Neuroreport 2000 11 3507 3511.
15. Buck AC, Schirmeister HH, Guhlmann CA et al. Ki-67 immunostaining in pancreatic cancer and chronic active pancreatitis: does in vivo FDG uptake correlate with proliferative activity? J. Nucl. Med. 2001 42 721 725. (Pubitemid 32453459)
16. Martin B, Paemans M, Mascaux C et al. Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. Br. J. Cancer 2004 91 2018 2025. (Pubitemid 40128768)
17. Prasad PD, Wang H, Huang W et al. Human LAT1, a subunit of system L amino acid transporter: molecular cloning and transporter function. Biochem. Biophys. Res. Commun. 1999 255 283 288. (Pubitemid 29292251)
18. Tamai S, Masuda H, Ishii Y, Suzuki S, Kanai Y, Endou H. Expression of L-type amino acid transporter 1 in a rat model of liver metastasis: positive correlation with tumor size. Cancer Detect. Prev. 2001 25 439 445.
19. Kim CH, Park KJ, Park JR et al. The RNA interference of amino acid transporter LAT1 inhibits the growth of KB human oral cancer cells. Anticancer Res. 2006 26 2943 2948. (Pubitemid 44161784)
20. Kanai Y, Endou H. Heterodimeric amino acid transporters: molecular biology and pathological and pharmacological relevance. Curr. Drug Metab. 2001 2 339 354. (Pubitemid 33133979)
21. Fuchs BC, Bode BP. Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? Semin. Cancer Biol. 2005 15 254 266. (Pubitemid 41065034)
22. Winton T, Livingston R, Johnson D et al. A prospective randomized trial of adjuvant vinorelbine (VNR) and cisplatin (CIS) in completely resected stage Ib and II non-small cell lung cancer (NSCLC). Intergroup JBR 10. N. Engl. J. Med. 2005 352 2589 2597.
23. Arriagada R, Bergman B, Dunant A et al. Cisplatin based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N. Engl. J. Med. 2004 350 351 360. (Pubitemid 38101630)
24. Douillard J, Rosell R, De Lena M et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomized control trial. Lancet Oncol. 2006 7 719 727. (Pubitemid 44283661)
25. Kato H, Ichinose Y, Ohta M et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N. Engl. J. Med. 2004 350 1713 1721. (Pubitemid 38501140)
26. Tsuboi M, Ohira T, Saji H et al. The present status of postoperative adjuvant chemotherapy for completely resected non-small cell lung cancer. Ann. Thorac. Cardiovasc. Surg. 2007 13 73 77.